Navigation Links
Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
Date:2/29/2008

MADISON, N.J., Feb. 29 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today the end of its collaboration agreements with Solvay Pharmaceuticals for the development and commercialization of bifeprunox as well as other compounds in earlier stages of development for the potential treatment of schizophrenia and other psychiatric conditions.

Wyeth terminated the collaboration with Solvay after assessing the opportunity for bifeprunox and determining it would not have sufficient commercial value for the two companies to share.

All development and commercialization rights in North America for bifeprunox, an investigational atypical antipsychotic, as well as global rights for the other compounds will now revert to Solvay Pharmaceuticals.

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Wyeth Announces Executive Change in Finance Organization
2. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
3. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
5. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
6. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
7. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
8. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
9. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
10. Wyeth Declares Preferred Stock Dividend
11. Wyeth Announces Election of New Principal Corporate Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... NEW YORK , September 2, 2014 ... Market Study on Membrane Technology in Pharmaceutical, Biopharma and ... Witness Highest Growth by 2019" the global membrane technology market for ... 7,029.9 million in 2014 and is expected to grow ... to reach an estimated value of USD 10,886.0 million ...
(Date:9/2/2014)... Opertech Bio, Inc., a company that ... approach to sensory evaluation, today announced the issuance ... Patent and Trademark Office, encompassing high-throughput sensory discrimination ... taste evaluation technology called Microtiter Operant Gustometer or ... for rapid characterization of taste sensory properties,” said ...
(Date:9/2/2014)... 2014  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... candidates targeting specific pathogens that cause serious infections ... final preclinical toxicology study of SYN-004. Per U.S. ... study was required to move the Company,s lead ... devastating effects of Clostridium difficile (C. difficile), ...
(Date:9/2/2014)... September 2, 2014 Culot brings ... and lab management services  BioData, producer of ... pleased to announce the appointment of Louis Culot ... served as VP Marketing and Business Development at BioDiscovery ... and clinical applications. Previously, Culot worked for ...
Breaking Biology Technology:Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5Louis Culot Appointed as BioData's CEO 2
... 6 Today, Pepscan reports,that it has achieved ... its,CLIPS-based synthetic peptide immunogen technology. By constructing synthetic,3D ... has induced functional,antibodies against the formerly intractable GPCR ... be involved in tumor angiogenesis. , ...
... today a strategic partnership with Scottsdale Clinical Research Institute ... cutting edge knowledge discovery and collaboration tools at ... more access to the latest therapies to treat cancer ... and communicate with each other about difficult cases. ...
... Communications Solution Demonstrated at HIMSS 2009BERKELEY HEIGHTS, N.J., ... (Nasdaq: ADAT ), a worldwide provider ... services, today announced that it has integrated Authentidate,s ... to improve hospital patient discharges. "Hospitals are looking ...
Cached Biology Technology:Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7 2MedTrust Online and Scottsdale Clinical Research Institute at Scottsdale Healthcare Announce Collaboration to Provide Cutting Edge Technology to Improve Patient Care 2Authentidate Teams with Nortel to Enhance Hospital Patient Discharge and Placement Processes 2Authentidate Teams with Nortel to Enhance Hospital Patient Discharge and Placement Processes 3Authentidate Teams with Nortel to Enhance Hospital Patient Discharge and Placement Processes 4
(Date:9/2/2014)... MD - The American Society of Human Genetics ... (NHGRI), part of the National Institutes of Health, ... at Northwestern University in Chicago, the newest ASHG/NHGRI ... begins today. , The Genetics and Public Policy ... develop and implement genetics-related health and research policy ...
(Date:9/2/2014)... PARK, Md. -- A team of University of ... they and other scientists say make possible new ... from clean energy and quantum computing advances to ... 2, issue of Nature Communications the ... synthesis strategy for hybrid nanostructures that uses a ...
(Date:9/2/2014)... [Brown University] It,s hard to comprehend how bad ... has become without knowing what it was before people ... rate was 10 times lower than scientists had thought, ... worse. , Extinctions are about 1,000 times more frequent ... came along. The explanation from lead author Jurriaan de ...
Breaking Biology News(10 mins):ASHG and NHGRI award genetics and public policy fellowship 2New synthesis method may shape future of nanostructures, clean energy 2New synthesis method may shape future of nanostructures, clean energy 3Extinctions during human era worse than thought 2Extinctions during human era worse than thought 3
... The Scripps Research Institute (TSRI) and the Takeda ... research collaboration to search for new drug targets for ... an initial collaboration launched in 2010 between scientists on ... led to several breakthroughs in identifying potential new compounds ...
... release is available in French . ... Sciences and his colleagues have unearthed a major scientific discovery ... Shale fossil beds, located in Yoho National Park. The fossils ... 505 million years old., Their study, to be published online ...
... March 13, 2013 Even after researchers studying White Nose ... is at the heart of the devastating disease, detecting ... This month, the journal Mycologia will publish research ... identifying additional species of Geomyces and describing development ...
Cached Biology News:Scripps Research and Takeda Pharmaceuticals announce expanded research collaboration 2Strange phallus-shaped creature provides crucial missing link 2More accurate, sensitive DNA test allows early identification of fungus causing WNS 2
Hybridization chamblers suitable for use with all ChIP-GLAS microarrays....
Integrins Sampler Kit 10g each...
Protein Tyrosine Phosphatase Sampler Kit 10g each...
... Solid phase reagent ... purification; Easy & unique ... Compatible with detergents and ... & recover non-envelop viruses ...
Biology Products: